- Home
- KOD vs PGEN Comparison
KOD vs PGEN Comparison
Compare KOD & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | PGEN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOD | PGEN |
|---|---|---|
| Price | $24.64 | $4.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $28.29 | $7.67 |
| AVG Volume (30 Days) | 854.6K | ★ 4.0M |
| Earning Date | 11-13-2025 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $1.92 | $1.11 |
| 52 Week High | $31.18 | $5.23 |
Technical Indicators
Market Signals| Indicator | KOD | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 59.57 |
| Support Level | $25.93 | $4.38 |
| Resistance Level | $29.49 | $5.10 |
| Average True Range (ATR) | 1.98 | 0.36 |
| MACD | -0.46 | 0.03 |
| Stochastic Oscillator | 12.77 | 71.37 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.